Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Adenocarcinoma, Bronchiolo-Alveolar
Interventions
DRUG

erlotinib

Erlotinib 150 mg/day (until progression)

DRUG

paclitaxel + carboplatine

Paclitaxel 90 mg/m² D1, D8, D15 (D1=D28, until progression) Carboplatine AUC 6 D1 (D1=D28, 6 cycles)

Trial Locations (9)

14000

Centre F. Baclesse, Caen

CHU - Pneumologie, Caen

38000

CHU Grenoble - pneumologie, Grenoble

42271

Institut de Cancérologie de la Loire, Saint-Priest-en-Jarez

63000

CHU Lyautey - Pneumologie, Strasbourg

75012

APHP - Saint-Antoine - pneumologie, Paris

75020

APHP - Hopital Tenon - Pneumologie, Paris

90016

Centre Hospitalier - Pneumologie, Belfort

93000

APHP - CHU Avicenne - Oncologie Medicale, Bobigny

All Listed Sponsors
lead

Intergroupe Francophone de Cancerologie Thoracique

OTHER

NCT00384826 - Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma | Biotech Hunter | Biotech Hunter